Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by lonc17on Mar 05, 2024 11:19pm
110 Views
Post# 35917222

RE:RE:RE:RE:RE:RE:RE:RE:RE:Need to clarify & very clear

RE:RE:RE:RE:RE:RE:RE:RE:RE:Need to clarify & very clearIntho, 

Perhaps you can refer me to the documentation in support of your claim. 

There are very reasons for which a "blackout period" would negate an insider's ability to exercise options. If you know of one for ONC then please share. 

Also, the reporting of "expiration of options" is a routine excercise that is not affected by a blackout.
Again, if you can direct me to ONC's documentation that might suggest otherwise I am pleased to have a look. 

It is very interesting that MC has let the mandated 5 days elapse since early December, without having reported the options as either exercised or expired. 

It is possible he is in non-compliance at with SEDI reporting requirements. 

That would be just another item to add to the list of concerns with MC.

I suggest you look at SEDI and specifically the 67 cases in which insiders of ONC have reported expriation of options. I can find one instance in 2010 when Douglas Ball reported the expiration one month late. In all other cases (less a few where info appears to be missing) the insiders were very diligent about reporting within 5 days of expiry. It appears to be a big deal and quite important in legal terms. 

The "blackout" defense for MC is suspect for two reasons:

1. There is absolutely no evidence or reason to suspect that ONC has been in a blackout period since the first week of December. In fact, that claim is absurd. 

2. It is highly unlikely that a blackout period would interfere with SEDI's legal requirement to report the status of MC's 175,000 options. 

I know I've given MC a lot of flak for letting his optiions expire. I'll be the first to admit I'm wrong if anyone can provide any evidence to the contrary.

<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse